How should a pregnancy with prenatal findings of trisomy 7 and trisomy 21 be managed and counseled?

Trisomy 7 and 21: Immediate Diagnostic Confirmation Required

Any prenatal finding suggesting both trisomy 7 and trisomy 21 requires immediate diagnostic testing with amniocentesis (not CVS) to definitively determine the true fetal karyotype, as this combination most likely represents confined placental mosaicism (CPM) rather than true fetal aneuploidy.

Understanding the Clinical Scenario

The simultaneous detection of trisomy 7 and trisomy 21 is highly unusual and raises critical diagnostic concerns:

• Trisomy 7 is not compatible with fetal survival and is never seen in liveborn infants
• True fetal trisomy 7 results in early pregnancy loss
• When detected prenatally, trisomy 7 almost always represents confined placental mosaicism - chromosomal abnormalities limited to placental tissue that do not affect the fetus itself 1

The detection of both trisomies simultaneously suggests this finding originated from placental-derived cell-free DNA (if detected by cfDNA screening) or from chorionic villi (if detected by CVS), not from the actual fetus.

Immediate Management Algorithm

Step 1: Determine the Source of the Finding

If detected by cell-free DNA (cfDNA) screening:

• cfDNA analyzes placental DNA circulating in maternal blood
• False-positive results occur due to CPM, vanishing twin, or maternal chromosomal mosaicism 1
• Diagnostic confirmation with amniocentesis is mandatory - never accept cfDNA results as diagnostic 1

If detected by chorionic villus sampling (CVS):

• CVS samples placental tissue, which may not reflect fetal karyotype
• Mosaicism on CVS cannot distinguish between CPM and true fetal mosaicism 2
• Follow-up amniocentesis is required 2

Step 2: Perform Amniocentesis for Definitive Diagnosis

Why amniocentesis, not CVS:

• Amniocentesis samples fetal cells directly from amniotic fluid
• Provides >99% detection rate for all aneuploidies with 0.2% risk of complications 1
• Avoids the CPM problem inherent to CVS and cfDNA 2

Testing approach on amniotic fluid:

• Full karyotype analysis (not just FISH) to evaluate all chromosomes
• Consider chromosomal microarray (CMA) to detect partial duplications or deletions 2
• If karyotype shows normal 46,XX or 46,XY, no additional metaphase counts are needed 2

Step 3: Genetic Counseling Based on Amniocentesis Results

If amniocentesis shows normal karyotype:

• The trisomy 7 and 21 findings represent CPM only
• Fetus is chromosomally normal
• However, CPM itself carries risks:
  • Increased risk of intrauterine growth restriction
  • Recommend third-trimester ultrasound for growth assessment
  • Consider antenatal surveillance starting at 36 weeks 3

If amniocentesis confirms trisomy 21 only:

• Trisomy 7 was CPM; trisomy 21 is real fetal aneuploidy
• Provide comprehensive counseling about Down syndrome
• Discuss pregnancy management options including continuation vs. termination
• Offer pediatric counseling and contact with families who have children with Down syndrome 4
• If continuing pregnancy: detailed anatomic ultrasound and fetal echocardiogram 5

If amniocentesis shows other findings:

• Rare scenarios include partial trisomies or complex mosaicism 6
• Requires specialized genetic counseling and maternal-fetal medicine consultation

Critical Counseling Points

Explain the Limitations of Screening Tests

Cell-free DNA screening is NOT diagnostic:

• 99% detection rate for trisomy 21 but 1-9% screen-positive rate includes false positives 1
• Cannot reliably detect all chromosomal abnormalities 1
• Positive predictive value for trisomy 21 is 91.8%, meaning ~8% of positive results are false positives 7
• For trisomy 13, PPV is only 37.2% 7

Address the Trisomy 7 Finding Specifically

• Trisomy 7 in prenatal testing always warrants investigation for CPM
• True fetal trisomy 7 is lethal and incompatible with ongoing pregnancy
• The presence of trisomy 7 alongside trisomy 21 strongly suggests the testing modality sampled placental rather than fetal tissue

Timing Considerations

• Do not delay waiting for additional screening results 5
• Amniocentesis can be performed from 15 weeks onward
• Earlier definitive diagnosis allows more time for decision-making and pregnancy management planning

Common Pitfalls to Avoid

1. Never accept cfDNA or CVS results as diagnostic - they require confirmation 1, 2

2. Do not perform repeat cfDNA testing - proceed directly to diagnostic testing 1

3. Avoid CVS for confirmation when mosaicism is suspected - amniocentesis is superior for distinguishing CPM from true fetal aneuploidy 2

4. Do not assume both trisomies are real - the combination is biologically implausible for a viable fetus

5. Do not neglect to evaluate for vanishing twin - this can cause discordant cfDNA results 7

Special Circumstances

In twin pregnancies:

• Discordant aneuploidy is possible 8, 9
• Each twin requires separate sampling during amniocentesis 9
• If monochorionic twins, two-sampling amniocentesis is essential to ensure independent sampling 9
• Discuss selective reduction options if one twin is affected 10, 8

If patient declines amniocentesis:

• Document thorough counseling about risks of unconfirmed diagnosis
• Detailed anatomic ultrasound at 18-22 weeks
• Fetal echocardiogram if trisomy 21 suspected 5
• Serial growth ultrasounds in third trimester
• Patient must understand they are proceeding without definitive diagnosis